Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.